Connect with us

IT Industry

Influenza Diagnostics Market Estimated to grow at 6.83% to reach $731.97 Million by 2024- Global Insights on Test Type (Traditional Diagnostic Test and Molecular Diagnostic Assay), Restraints, Drivers and Future Trends: Orbis Research

GlobeNewswire

Published

on

Reading Time: 4 minutes

Orbisresearch.com has published “Influenza Diagnostics Market-Growth, Trends, and Forecast (2019-2024)” research study to its database. rapid influenza diagnostic test (RIDT) market estimated to grow at 6.87% CAR during forecast period

Dallas, Texas, Aug. 24, 2019 (GLOBE NEWSWIRE) — Influenza is recognized as a crucial cause of morbidity and mortality in the human population, which is leading to the development and use of diagnostics that are intended for reducing consequent health and economic impacts. According to WHO, in 2018, influenza caused severe sickness or death mainly in patients at a high risk and illness range from mild to severe and even death. Also, this annual increase is projected to result in about 3-5 million cases of severe illness, and about 290,000-650,000 deaths, globally.

Various initiatives and research funding are bolstering the growth of the market. For instance, National Institute of Allergy and Infectious Disease (NIAID) has supported a broad portfolio of the influenza research, which includes studies that are informing the development of vaccines, diagnostics, and therapeutics against seasonal and pandemic influenza. Similarly, in 2018, a non-profit association between academic, government, and industry medical researchers, called Human Vaccine Project, launched the Universal Influenza Vaccine Initiative. Thus, growth in research funding by the government and companies for influenza diagnostics is driving the market.

Request a pdf sample@https://www.orbisresearch.com/contacts/request-sample/3585363

The global influenza diagnostics market was valued at USD 492.42 million in 2018, and is estimated to be valued at USD 731.97 million in 2024, witnessing a CAGR of 6.83%. Certain factors that are driving the market growth include increasing prevalence of influenza and related chronic diseases, growth in research funding for influenza diagnostics, and rising demand for early diagnosis and control of influenza.

However, it is critical to ensure that all the rapid antigen flu tests meet new FDA requirements for approval. Hence, the stringent FDA regulations act as significant restraints for the market.

Scope of the Report

Influenza, also known as flu, is a highly contagious infectious disease caused by a virus. This is an infection of the respiratory passages, which causes fever and severe aches. The influenza diagnostic market includes the tests that are conducted for the diagnosis of influenza cases. As per the scope of this report, only the test kits and reagents that are being used for the diagnosis of influenza have been taken into account for the calculation of the total market size.

Key Market Trends

Rapid Influenza Diagnostic Test (RIDT) is Expected to hold its Highest Market Share in the Test Type Segment

In the test type segment of the influenza diagnostics market, among all traditional diagnostic tests, the rapid influenza diagnostic test (RIDT) is believed to have the largest market size and is expected to witness a CAGR of 6.87% during the forecast period.

Rapid influenza diagnostic tests (RIDTs) are immunoassays, which help to identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and qualitatively provide the results. It can diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms.

The rising popularity of RIDT is due to the benefits of a faster result and simple usage. Some of the RIDTs are also approved for office/bedside use as well. The RIDT segment is also expected to witness rapid growth, as a result of their common usage in point-of-care settings.

However, one of the major drawback associated with RIDT is that it gives false negative results, due to its low to moderate sensitivities (50-70%). Healthcare policymakers began to recognize the impact of its low sensitivity in 2009 when the novel H1N1 influenza epidemic occurred.

Browse the full research report@https://www.orbisresearch.com/reports/index/influenza-diagnostics-market-growth-trends-and-forecast-2019-2024

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for influenza diagnostics and is expected to continue its stronghold for a few more years.

As per data published by the Centers for Disease Control and Prevention (CDC), RIDTs are commonly available across the region. The reason behind the wide availability of the test is the reduced time span needed to generate results. RIDT can yield results in 15 minutes. With increasing influenza-associated hospitalization and pediatric deaths and the interest of government organizations to better manage the disease, the North American influenza diagnostics market is expected to grow in the future.

Direct purchase a single user copy@https://www.orbisresearch.com/contact/purchase-single-user/3585363

Competitive Landscape

The influenza diagnostics market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Coris BioConcept, DiaSorin SpA, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Quidel Corporation, and Sekisui Diagnostics., among others, hold the substantial share in the market.

Various developments have recently been taking place in the market; for instance, in March 2018, Sekisui Diagnostics launched the Silaris Influenza A and B test, developed in collaboration with Mesa Biotech. Also, in October 2017, Abbott Laboratories acquired Alere Inc. (Alere), a diagnostic device and service provider, which strengthened the company’s diagnostics presence.

Major points from Table of Contents:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
 Continued…

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +91 895 659 5155
Email ID: enquiry@orbisresearch.com   
Follow Us on Linkedin: https://www.linkedin.com/company/orbisresearch

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

IT Industry

IDEX begins deliveries of its dual-interface sensor to world class electronics manufacturer

GlobeNewswire

Published

on

Reading Time: 1 minute

Oslo, Norway, 15 October 2019: IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has received a purchase order and initiated production ramp preparations to fulfill a multi-year order commitment signed with a leading provider of global financial news and IT services, as announced in April this year.

As part of this multimillion-dollar commitment IDEX is supplying its dual-interface sensors to one of the world’s largest electronics manufacturing service companies in order to qualify their manufacturing process; a critical step in any ramp-up process.

Stan Swearingen, CEO of IDEX Biometrics comments: “This is an exciting time for IDEX as we gear up volume production with our partners in what will be a cutting-edge, secure access solution. We now expect a regular flow of purchase orders from this customer and look forward to being an integral part of the rollout of their enhanced biometric security solutions”.

For further information contact:
Stuart Hunt, Head of Investor Relations & Communications
+44 (0)1276 534 632

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is the leading provider of fingerprint identification technologies offering simple, secure and personal authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast-growing multi-billion-unit opportunity.

For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue Reading

IT Industry

Global e∙dentity™ files its third formal USPTO 37CFR1.290 request in six months against Apple AAPL (NASDAQ)

GlobeNewswire

Published

on

Reading Time: 1 minute

WILMINGTON, Del., Oct. 15, 2019 (GLOBE NEWSWIRE) — Global e∙dentity™, founded by Robert Adams, U.S. Navy veteran who along with the most amazing engineers & team, have developed and patented the next generation of identity protocol methods, has now filed its third 37CFR1.290 request with the USPTO within in six months against Apple; the formal third-party review request with the USPTO is in opposition to Apple newest patent application 16/262032 published on September 12, 2019. Adams stated that Global e∙dentity™ had “no choice, and once again, file a new third-party action with the USPTO in response to Apple’s latest published patent application.”  USPTO new third party filing is noted on the Global e·dentity™ website: https://www.globaledentity.com/third-party-review-uspto3/

Global e∙dentity™ was featured on Featured on KRON4 — San Francisco Bay Area’s Local TV www.globaledentity.com/2019/06/22/kron4-apple-intellectual-property-theft-and-patent-violations with regards the first of two third-party actions with the USPTO against Apple.  Adams continued, “We are indeed flattered that Apple has now filed, not one, not two, but now a third patent application based on our already patented technology 10,135,822 Biometric authentication of individuals utilizing characteristics of bone and blood vessel structures and its continuation patents.   Having said that, the key question remains: Why did Apple fail to inform the USPTO they had in their possession per their request, all of our trade secrets and provisional patent as early as March/April 2017 when negotiations started between representatives of Apple and Global e∙dentity?”

Global e·dentity™, is young well-funded tech start-up company with national security applications in mind; providing secure multi-factor biometric and digital identity solutions. For more information, visit www.globaledentity.com. Global e·dentity™ and product are either registered trademarks or trademarks of You are the ID ™ LLC in the United States and/or other countries.

For more information, press only: Sophia Miller  sophiam@globaledentity.com

Continue Reading

IT Industry

Digia Plc will publish its business review January-September 2019 on October 31, 2019

GlobeNewswire

Published

on

Reading Time: 1 minute

Digia Plc
Investor News
15 October 2019 at 09:00 am


Digia Plc will publish its business review January-September 2019 on Thursday 31 October at 8:00 am EET (GMT +2). After the publishing the report is available on: https://digia.com/en/investors/stock-exchange-releases/.

Timo Levoranta, President & CEO, and Kristiina Simola, CFO, will present the financial results in Finnish at an analyst and press conference in Helsinki on Thursday, October 31, 2019 at 11.00 am (EET). The conference will take place at Business Meeting Park in Helsinki (address: Forum, Mannerheimintie 20 B, 6th floor. Entrance from the glass corner of Mannerheimintie and Simonkatu).

The material and presentation for the event will be available from 11 am on October 31, 2019 in the Investors section of the company’s website: www.digia.com/en/investors/reports-and-presentations.

Digia Oyj
Timo Levoranta, CEO


Additional information:

Kristiina Simola, CFO, tel. +358 40 756 3132

Distribution:
Nasdaq Helsinki
Key media
digia.com

Digia is a software and service company that helps its customers renew themselves digitally. There are more than 1,200 of us working at Digia. Our roots are in Finland and we operate with our customers in Finland and abroad. world. We are building a world in which digitalisation makes a difference. Digia net sales were EUR 112.1 million in 2018. The company is listed on Nasdaq Helsinki (DIGIA). digia.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off